Skip to content
Screener

Total Revenue at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$11.99B—
Labcorp Holdings logo
Labcorp HoldingsLH
$3.73B+5.8%
IQVIA logo
IQVIAIQV
$4.37B+8.7%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$678.2M-4.5%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$34.17M—
NeoGenomics logo
NeoGenomicsNEO
$201.66M+11.2%

Segments

By product

See full
Oncology$219.07M+48.1%
Metabolic$209.37M+11.0%
Other$98.28M-16.8%
Cardiology$82.86M+35.5%
Central Nervous System$59.98M+2.4%
AVAI$37.77M+29.8%

By segment

See full
Reportable Segment$707.33M+17.2%

Other financials

Income statement

See full
Operating income$146.8M+16.2%
Net income$121.4M+34.5%
EPS (diluted)$4.25+37.1%

Balance sheet

See full
Cash & equivalents$502.7M+985%
Total debt$144.1M-3.8%
Total equity$433.9M+152%
Total assets$2.1B+30.9%

Cash flow

See full
Operating cash flow$162.0M+9.1%
CapEx$23.9M+291%
Free cash flow$138.1M-3.0%

Valuation

See full
Market cap$16.69B+10.8%
Enterprise value$16.33B+9.5%
P/E34×-0.8×
P/S6×-0.4×

Profitability

See full
Operating margin21%-0.4pp
Net margin17.7%-1.1pp
FCF margin25.4%-0.6pp

Returns & leverage

See full
Return on equity162.2%+72.8pp
Debt / equity0.3×-0.5×
Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001668397-26-000025
(Amounts in thousands, except per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue, net (includes $4.7 million and $16.9 million with related parties for the three months ended June 30, 2026 and 2025, respectively, and $12.0 million and $30.7 million with related parties for the six months ended June 30, 2026 and 2025, respectively)$707,331$603,311$1,413,935$1,161,881
Operating expenses:
Direct service costs, excluding depreciation and amortization202,555185,826400,829363,642
Reimbursed out-of-pocket expenses303,139237,472615,143439,876
Total direct costs505,694423,2981,015,972803,518
Selling, general and administrative48,10346,66496,020104,561
Depreciation6,5556,77713,30613,471
Amortization155237310473

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s total revenue?
Medpace Holdings, Inc. (MEDP) reported total revenue of $707.33M in Q2 2026.
How has Medpace Holdings, Inc.'s total revenue changed year-over-year?
Medpace Holdings, Inc.'s total revenue increased by 17.2% year-over-year, from $603.31M to $707.33M.
What is the long-term trend for Medpace Holdings, Inc.'s total revenue?
Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s total revenue has grown at a 22.0% compound annual growth rate (CAGR), from $1.14B to $2.53B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Medpace Holdings, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude